Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 88

1.

[Acute myeloid leukemia].

Yamaguchi H.

Rinsho Ketsueki. 2013 Jan;54(1):39-48. Review. Japanese. No abstract available.

PMID:
23391646
2.

[New clinical evidence and drugs].

Kobayashi Y.

Rinsho Ketsueki. 2013 Oct;54(10):1660-70. Review. Japanese. No abstract available.

PMID:
24064815
3.

SnapShot: Acute myeloid leukemia.

Zeisig BB, Kulasekararaj AG, Mufti GJ, So CW.

Cancer Cell. 2012 Nov 13;22(5):698-698.e1. doi: 10.1016/j.ccr.2012.10.017. No abstract available.

4.

Differential prognosis impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia.

Boissel N, Nibourel O, Renneville A, Huchette P, Dombret H, Preudhomme C.

Blood. 2011 Mar 31;117(13):3696-7. doi: 10.1182/blood-2010-11-320937. No abstract available.

5.

Prognostic value of immunophenotyping and gene mutations in elderly patients with acute myeloid leukemia with normal karyotype.

Dang H, Jiang A, Kamel-Reid S, Brandwein J, Chang H.

Hum Pathol. 2013 Jan;44(1):55-61. doi: 10.1016/j.humpath.2012.04.008. Epub 2012 Aug 28.

PMID:
22939316
6.

Molecular characterization of acute myeloid leukemia and its impact on treatment.

Frankfurt O, Licht JD, Tallman MS.

Curr Opin Oncol. 2007 Nov;19(6):635-49. Review.

PMID:
17906465
7.

Acute myeloid leukemia in the elderly.

Ho C, Butera JN.

Med Health R I. 2011 Jan;94(1):7-9. No abstract available.

PMID:
21290987
8.

Leukemic stem cell gene expression signature and clinical outcomes in acute myeloid leukemia.

Masuda S.

JAMA. 2011 Mar 16;305(11):1094; author reply 1094-5. doi: 10.1001/jama.2011.299. No abstract available.

PMID:
21406645
9.

Clinical implications of gene expression profiling of acute myeloid leukemia.

Mills KI, Gilkes AF.

Curr Hematol Malig Rep. 2006 Jun;1(2):114-21. doi: 10.1007/s11899-006-0022-7. Review.

PMID:
20425341
10.

New opportunities and new problems for acute myeloid leukemia treatment.

Lahortiga I, Cools J.

Haematologica. 2012 Jun;97(6):796. doi: 10.3324/haematol.2012.070243. No abstract available.

11.

High proportion of leukemic stem cells at diagnosis is correlated with unfavorable prognosis in childhood acute myeloid leukemia.

Witte KE, Ahlers J, Schäfer I, André M, Kerst G, Scheel-Walter HG, Schwarze CP, Pfeiffer M, Lang P, Handgretinger R, Ebinger M.

Pediatr Hematol Oncol. 2011 Mar;28(2):91-9. doi: 10.3109/08880018.2010.528171. Epub 2011 Jan 8.

PMID:
21214408
12.

[Acute myeloid leukemia: from risk-adapted to genotype-specific therapy].

Kayser S, Schlenk RF.

Dtsch Med Wochenschr. 2011 Aug;136(31-32):1577-80. doi: 10.1055/s-0031-1281556. Epub 2011 Aug 1. Review. German. No abstract available.

PMID:
21809245
13.

The prognostic impact of germline 46/1 haplotype of Janus kinase 2 in cytogenetically normal acute myeloid leukemia.

Nahajevszky S, Andrikovics H, Batai A, Adam E, Bors A, Csomor J, Gopcsa L, Koszarska M, Kozma A, Lovas N, Lueff S, Matrai Z, Meggyesi N, Sinko J, Sipos A, Varkonyi A, Fekete S, Tordai A, Masszi T.

Haematologica. 2011 Nov;96(11):1613-8. doi: 10.3324/haematol.2011.043885. Epub 2011 Jul 26.

14.

Prognostic impact of white blood cell count in intermediate risk acute myeloid leukemia: relevance of mutated NPM1 and FLT3-ITD.

de Jonge HJ, Valk PJ, de Bont ES, Schuringa JJ, Ossenkoppele G, Vellenga E, Huls G.

Haematologica. 2011 Sep;96(9):1310-7. doi: 10.3324/haematol.2011.040592. Epub 2011 May 23.

15.

N-ras mutation in acute myeloid leukemia: incidence, prognostic significance and value as a marker of minimal residual disease.

Casey G, Rudzki Z, Roberts M, Hutchins C, Juttner C.

Pathology. 1993 Jan;25(1):57-62.

PMID:
8316501
16.

Molecular characterization of acute myeloid leukemia.

Döhner K, Döhner H.

Haematologica. 2008 Jul;93(7):976-82. doi: 10.3324/haematol.13345. No abstract available.

17.

A 28-year-old man with leukocytosis and anemia.

Narmala SK, Gandla KK, Verghese C, Bourgeois K, Boulmay BC.

J La State Med Soc. 2010 Jan-Feb;162(1):8-13. No abstract available.

PMID:
20336951
18.

[Risk-adapted therapy in acute myeloid leukemia].

Fiegl M, Hiddemann W.

Internist (Berl). 2012 Apr;53(4):392, 394-9. doi: 10.1007/s00108-011-2986-1. German.

PMID:
22410942
19.

Integrative analysis of type-I and type-II aberrations underscores the genetic heterogeneity of pediatric acute myeloid leukemia.

Balgobind BV, Hollink IH, Arentsen-Peters ST, Zimmermann M, Harbott J, Beverloo HB, von Bergh AR, Cloos J, Kaspers GJ, de Haas V, Zemanova Z, Stary J, Cayuela JM, Baruchel A, Creutzig U, Reinhardt D, Pieters R, Zwaan CM, van den Heuvel-Eibrink MM.

Haematologica. 2011 Oct;96(10):1478-87. doi: 10.3324/haematol.2010.038976. Epub 2011 Jul 26.

20.

[Genetic alterations in AML].

Sanada M.

Rinsho Ketsueki. 2013 Oct;54(10):1651-9. Review. Japanese. No abstract available.

PMID:
24064814

Supplemental Content

Support Center